新型冠状病毒引起肝损伤的研究现状

周亚宁; 冯巩; 刘曼玲; 严琴琴; 范立萍; 弥曼

doi:10.3969/j.issn.1001-5256.2020.06.047

新型冠状病毒引起肝损伤的研究现状

DOI: 10.3969/j.issn.1001-5256.2020.06.047

1. 西安医学院研究生院
2. 西安医学院全科医学研究所

基金项目:

陕西省普通高等学校优势学科建设项目(陕教位[2014]3号文件)；

详细信息

中图分类号: R563.1;R575
计量
- 文章访问数: 671
- HTML全文浏览量: 55
- PDF下载量: 151
- 被引次数: 0
出版历程
- 出版日期: 2020-06-20

Current status of the research on liver injury caused by SARS-CoV-2

Research funding:

摘要

摘要:
2019年新型冠状病毒（SARS-CoV-2）引起的病毒性肺炎在中国武汉爆发,对公众健康构成重大威胁。SARS-CoV-2与严重急性呼吸综合征相关冠状病毒（SARS-CoV）和中东呼吸综合征相关冠状病毒（MERS-CoV）高度同源,都会导致严重的呼吸道症状。除呼吸系统症状外,相当比例的SARS和SARS-CoV-2感染者出现不同程度的肝损伤,但其流行病学特征和发生机制尚不明确。在总结SARS-CoV-2流行病学基础上,重点阐述SARS-CoV-2及其所致肝损伤的可能机制和有效治疗方案的研究现状,为SARS-CoV-2感染者肝损伤的防治提供参考和研究思路。
- 新型冠状病毒 /
- 肝损伤 /
- 病理过程 /
- 治疗学
Abstract:
The outbreak of viral pneumonia caused by severe acute respiratory syndrome coronavirus 2( SARS-CoV-2) in Wuhan,China poses a major threat to public health. SARS-CoV-2 is highly homologous to severe acute respiratory syndrome-associated coronavirus and Middle East respiratory syndrome-associated coronavirus,all of which may cause severe respiratory symptoms. In addition to respiratory symptoms,a considerable proportion of patients with SARS and SARS-CoV-2 infection have varying degrees of liver injury,but their epidemiological features and pathogenesis remains unclear. This article summarizes the epidemiology of SARS-CoV-2 and elaborates on the current status of the research on SARS-CoV-2,possible mechanism of liver injury caused by SARS-CoV-2,and effective treatment regimens,so as to provide a reference and new research ideas for the prevention and treatment of liver injury in patients with SARS-CoV-2 infection.
- SARS-CoV-α /
- liver injury /
- pathologic processes /
- therapeutics

HTML全文

参考文献(45)

[1] TIAN HY. 2019-n Co V:New challenges fromcoronavirus[J].Chin J Prev Med,2020,54(2):e001.(in Chinese)田怀玉．2019-n Co V:来自冠状病毒的新挑战[J]．中华预防医学杂志，2020,54(2):e001.

[2] World Health Organization. Novel Coronavirus(2019-n Co V)situation report[EB/OL].(2020)[2020-02-24]. https://www. who. int/emergencies/diseases/novel-coronavirus-2019/situation-reports.

[3] WANG FS,ZHANG C. What to do next to control the 2019-n Co V epidemic?[J]. Lancet,2020,395(10222):391-393.

[4] GUAN WJ,NI ZY,HU Y,et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med,2020.[Online ahead of print]

[5] CHEN N,ZHOU M,DONG X,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:A descriptive study[J]. Lancet,2020,395(10223):507-513.

[6] LI Q,GUAN X,WU P,et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia[J]. N Engl J Med,2020.[Online ahead of print]

[7] CALLAWAY E,CYRANOSKI D. China coronavirus:Six questions scientists are asking[J]. Nature,2020,577(7792):605-607.

[8] CHAN JF,YUAN S,KOK KH,et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission:A study of a family cluster[J]. Lancet,2020,395(10223):514-523.

[9] ROTHE C,SCHUNK M,SOTHMANN P,et al. Transmission of2019-n Co V infection from an asymptomatic contact in Germany[J]. N Engl J Med,2020,382(10):970-971.

[10] HOLSHUE ML,DEBOLT C,LINDQUIST S,et al. First case of2019 novel coronavirus in the United States[J]. N Engl J Med,2020,382(10):929-936.

[11] WANG D,HU B,HU C,et al. Clinical characteristics of 138hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J]. JAMA,2020.[Online ahead of print]

[12] YANG Y,LU QB,LIU MJ,et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in china[J].medRxiv,2020.[Online ahead of print]

[13] ZHAO Y,ZHAO ZX,WANG YJ,et al. Single-cell RNA expression profiling of ACE2,the putative receptor of Wuhan2019-n Cov[J]. BioRxiv,2020.[Online ahead of print]

[14] FANG D,MA JD,GUAN JL,et al. Manifestations of digestive system in hospitalized patients with novel coronavirus pneumonia in Wuhan,China:A single-center,descriptive study[J].Chin J Dig,2020.[Online ahead of print](in Chinese)方丹，马敬东，官佳轮，等．武汉地区新型冠状病毒肺炎住院患者消化系统表现的单中心、描述性研究[J]．中华消化杂志，2020.[Epub ahead of print]

[15] CHEN LP,LI WX,TIAN C,et al. Advances in the digestive system of coronavirus infected patients[J]. Chin J Dig,2020.[Online ahead of print](in Chinese)陈丽萍，李微霞，田成，等．冠状病毒感染患者消化系统表现的研究进展[J]．中华消化杂志，2020.[Online ahead of print]

[16] HUANG C,WANG Y,LI X,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet,2020,395(10223):497-506.

[17] SHI H,HAN X,JIANG N,et al. Radiological findings from 81patients with COVID-19 pneumonia in Wuhan,China:A descriptive study[J]. Lancet,2020.[Online ahead of print]

[18] ZHANG C,SHI L,WANG FS. Liver injury in COVID-19:Management and challenges[J]. Lancet Gastroenterol Hepatol,2020.[Online ahead of print]

[19] LU CW,LIU XF,JIA ZF. 2019-n Co V transmission through the ocular surface must not be ignored[J]. Lancet,2020,395(10224):e39.

[20] XIA J,TONG J,LIU M,et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-Co V-2 infection[J]. J Med Virol,2020.[Online ahead of print]

[21] LAN L,XU D,YE G,et al. Positive RT-PCR test results in patients recovered from COVID-19[J]. JAMA,2020.[Online ahead of print]

[22] The Hong Kong SAR government press release said the dogs were weak in tests for the 2019 coronavirus[2020-02-28].http://www. info. gov. hk/gia/general/202002/28/P2020022800012. htm.(in Chinese)香港特别行政区政府新闻公报，狗只对2019冠状病毒测试呈弱阳性反应[2020-02-28]. http://www. info. gov. hk/gia/general/202002/28/P2020022800012. htm.

[23] WAN Y,SHANG J,GRAHAM R,et al. Receptor recognition by the novel coronavirus from Wuhan:An analysis based on decade-long structural studies of SARS coronavirus[J]. J Virol,2020,94(7):e00127-20.

[24] ZHOU P,YANG XL,WANG XG,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J].Nature,2020,579(7798):270-273.

[25] CHAU TN,LEE KC,YAO H,et al. SARS-associated viral hepatitis caused by a novel coronavirus:Report of three cases[J]. Hepatology,2004,39(2):302-310.

[26] ALSAAD KO,HAJEER AH,AL BALWI M,et al. Histopathology of Middle East respiratory syndrome coronovirus(MERSCo V)infection-clinicopathological and ultrastructural study[J]. Histopathology,2018,72(3):516-524.

[27] CHAI X,HU L,ZHANG Y,et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-n Co V infection[J]. bioRxiv,2020.[Online ahead of print]

[28] FAN CB,LI K,DING YH,et al. ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-n Co V infection[J]. medRxiv,2020.[Online ahead of print]

[29] NICHOLLS JM,POON LL,LEE KC,et al. Lung pathology of fatal severe acute respiratory syndrome[J]. Lancet,2003,361(9371):1773-1778.

[30] WONG CK,LAM CW,WU AK,et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome[J]. Clin Exp Immunol,2004,136(1):95-103.

[31] KONG SL,CHUI P,LIM B,et al. Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients[J]. Virus Res,2009,145(2):260-269.

[32] CHU H,ZHOU J,WONG BH,et al. Productive replication of Middle East respiratory syndrome coronavirus in monocytederived dendritic cells modulates innate immune response[J].Virology,2014,454-455:197-205.

[33] CHANNAPPANAVAR R,PERLMAN S. Pathogenic human coronavirus infections:Causes and consequences of cytokine storm and immunopathology[J]. Semin Immunopathol,2017,39(5):529-539.

[34] CHU H,ZHOU J,WONG BH,et al. Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways[J]. J Infect Dis,2016,213(6):904-914.

[35] HUANG A,YANG XR,SUN HC,et al. Mechanism and prevention and treatment of liver injury associated with new coronavirus pneumonia[J]. Chin J Dig Surg,2020.[Online ahead of print](in Chinese)黄傲，杨欣荣，孙惠川，等．新型冠状病毒肺炎相关肝损伤的发生机制及防治措施[J]．中华消化外科杂志，2020.[Epub ahead of print]

[36] YANG L,WANG W,WANG X,et al. Creg in hepatocytes ameliorates liver ischemia/reperfusion injury in a TAK1-dependent manner in mice[J]. Hepatology,2019,69(1):294-313.

[37] XU Z,SHI L,WANG Y,et al. Pathological findings of COVID-19associated with acute respiratory distress syndrome[J]. Lancet Respir Med,2020.[Online ahead of print]

[38] General office of the national health commission. Diagnosis and treatment of pneumonia caused by novel coronavirus(The sixth edition)(2020-02-18)[EB/OL]. http://www. nhc. gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817. pdf.(in Chinese)国家卫生健康委办公厅．新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL]. http://www. nhc. gov. cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817. pdf.

[39] LI HY,YANG CP,JIN HT. Research progress in the pathogenesis of liver injury caused by commonly used drugs[J].Chin J Pharmacov,2019,16(12):750-756.(in Chinese)李红颖，杨翠平，靳洪涛．常用药物肝损伤发生机制研究进展[J]．中国药物警戒，2019,16(12):750-756.

[40] SANTOS R,SAMPAIO WO,ALZAMORA AC,et al. The ACE2/Angiotensin-(1-7)/MAS axis of the renin-angiotensin system:Focus on angiotensin-(1-7)[J]. Physiol Rev,2018,98(1):505-553.

[41] DING Y,WANG H,SHEN H,et al. The clinical pathology of severe acute respiratory syndrome(SARS):A report from China[J]. J Pathol,2003,200(3):282-289.

[42] SUN ML,YANG JM,SUN YP,et al. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia[J]. Chin J Tuberc Respir Dis,2020.[Online ahead of print](in Chinese)孙美丽，杨建民，孙玉萍，等．RAS抑制剂是治疗新型冠状病毒肺炎的可能选择之一[J]．中华结核和呼吸杂志，2020.[Epub ahead of print]

[43] CHEN H,DU Q. Potential natural compounds for preventing SARS-Co V-2(2019-n Co V)infection[J]. Preprints,2020.[Epub ahead of print]

[44] European Association for the Study of the Liver. EASL clinical practical guidelines on the management of acute(fulminant)liver failure[J]. J Hepatol,2017,66(5):1047-1081.

[45] FLAMM SL,YANG YX,SINGH S,et al. American Gastroenterological Association Institute guidelines for the diagnosis and management of acute liver failure[J]. Gastroenterology,2017,152(3):644-647.

施引文献

资源附件(0)

访问统计